A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL is a PHASE3 clinical asset sponsored by Sarcoma Alliance for Research through Collaboration in Gastrointestinal Stromal Tumors. SEO and diligence focus: Imatinib mesylate, Imatinib mesylate, Imatinib mesylate, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.